Mounjaro and DVA: Can You Get Tirzepatide on the RPBS?

It is not on the PBS or the RPBS

Search the PBS for tirzepatide or Mounjaro and you get nothing. Check the Repatriation Schedule of Pharmaceutical Benefits and it is not there either.

That matters more than it sounds. Restriction criteria — the BMI thresholds, the authority wording, the number of repeats, the rules about when treatment must stop — live inside a PBS or RPBS listing. No listing means no published criteria. If you have read a confident article quoting a specific BMI cut-off for DVA-funded Mounjaro, it was not quoting DVA, because DVA has not published one.

For comparison, semaglutide is PBS-listed, but for type 2 diabetes — not for weight management. Weight-management GLP-1 therapy in Australia is overwhelmingly a private, full-cost proposition.

The unlisted-item pathway

Not listed does not mean not fundable. DVA is explicit that “there can be a misconception that DVA will not subsidise an item if it is not listed”. There is a defined process for items on neither schedule:

Your doctor applies for prior approval before prescribing, using the RPBS Unlisted, Non-Scheduled Authority Prescription request form via HPOS form upload.
Applications are assessed by the Veterans’ Affairs Pharmaceutical Advisory Centre (VAPAC).
Telephone approvals are available on 1800 552 580, and the form is not required for those.
Decisions are made case by case on the clinical information supplied. There is no checklist published in advance.

Your card determines the starting point. A Gold Card covers treatment for all conditions. A White Card covers only accepted conditions and non-liability health care conditions. So for a White Card holder, the entire question is whether the treatment relates to an accepted condition — which is why what is on your accepted list matters here as much as the clinical argument.

The indication that fits veterans

Mounjaro is TGA-registered in Australia for three things, and the third is the one most veterans do not know about:

Type 2 diabetes mellitus — approved January 2023, for adults with insufficiently controlled T2DM as an adjunct to diet and exercise.
Chronic weight management — approved 2024, as an adjunct to a reduced-calorie diet and increased physical activity.
Moderate to severe obstructive sleep apnoea in adults with obesity — added 27 May 2025.

That third indication is worth pausing on. Obstructive sleep apnoea is one of the more commonly accepted DVA conditions, and it is frequently accepted alongside conditions that make weight gain hard to avoid — chronic musculoskeletal pain that limits exercise, mental health conditions, and the medications used to treat them.

A veteran with accepted OSA, obesity, and moderate to severe disease on polysomnography is therefore in a materially different position from one seeking weight-loss treatment generally. The treatment is TGA-approved for that exact indication, and the indication maps onto a condition DVA has already accepted. That is the strongest version of the argument, and it is the one worth putting.

If OSA is not yet on your accepted list but is documented in your record, that is a claims question before it is a prescribing question — see chart reviews.

What Mounjaro is and how it works

Mounjaro is the brand name for tirzepatide, a once-weekly subcutaneous injection. It is a dual GIP and GLP-1 receptor agonist — it acts on two incretin hormone pathways rather than one, which is what distinguishes it from the GLP-1-only agents such as semaglutide.

The effects that matter clinically: it increases glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and acts on appetite regulation centrally — producing earlier satiety and reduced food intake. Dosing starts low and is titrated up over weeks to manage gastrointestinal side effects.

Benefits and risks

Benefits. Substantial and sustained weight reduction in people with obesity; improved glycaemic control in type 2 diabetes; and, for the OSA indication, reduction in apnoea-hypopnoea severity that follows from the weight loss. For a veteran whose knees, back and sleep are all made worse by weight, the downstream effects can be significant.

Risks and common adverse effects. Gastrointestinal effects dominate — nausea, vomiting, diarrhoea, constipation, abdominal pain — usually worst during dose escalation. Also reported: injection-site reactions, fatigue, gallbladder disease including cholelithiasis, and pancreatitis. The class carries a boxed warning regarding thyroid C-cell tumours observed in rodents; it is contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2. Caution applies in gastroparesis and significant gastrointestinal disease, and it is not for use in pregnancy.

The TGA has also issued safety communications about this class generally — worth your prescriber being current on them rather than relying on a summary.

Interactions worth knowing

Insulin and sulfonylureas. The combination raises hypoglycaemia risk materially. Doses of the insulin or sulfonylurea usually need reducing, with closer glucose monitoring.
Oral medicines generally. Delayed gastric emptying can alter how and when oral drugs are absorbed. This matters most for medicines with a narrow therapeutic index and for anything where timing is critical.
Oral contraceptives. Reduced effectiveness has been raised with this class, particularly around dose escalation; non-oral contraception or additional barrier precautions are commonly advised for a period after starting and after each dose increase.
Warfarin and other narrow-index drugs. Worth more frequent monitoring when starting or escalating.
Anything that slows the gut further — opioids being the obvious one in a veteran population with chronic pain — compounds the gastrointestinal effects.

This is a summary for orientation, not a prescribing reference. The current Australian Product Information is the authority.

On BMI rules and stopping rules

We are asked constantly what BMI you need, how long the script runs, and at what BMI DVA stops paying. The honest answer is that none of those figures exist as published DVA criteria, because there is no listing for them to attach to.

What exists instead is clinical judgement assessed case by case. A strong application is one that documents the things any reasonable assessor would want to see: the accepted condition the treatment relates to, objective measurements rather than assertions, what has already been tried and why it did not work, the TGA-approved indication being relied on, and what will be monitored and reviewed. An application that reads as a weight-loss request with no link to an accepted condition is a weak one.

If anyone quotes you a specific DVA BMI threshold for tirzepatide, ask them where it is published. We could not find one, and we looked.

Common questions

Is Mounjaro on the PBS?

No. Tirzepatide returns no results on the PBS medicine search and does not appear in the Repatriation Schedule.

Will DVA pay for Mounjaro?

Only via prior approval as an unlisted, non-scheduled item, assessed case by case by VAPAC. There is no guarantee, and no published criteria to meet in advance.

Do I need an accepted condition?

For a White Card, yes — RPBS covers accepted and non-liability conditions only. A Gold Card covers treatment for all conditions.

What BMI do I need?

DVA has not published one for this medicine. Anyone stating a specific DVA threshold should be asked for the source.

Is there an indication that helps a DVA case?

Mounjaro is TGA-approved for moderate to severe obstructive sleep apnoea in adults with obesity. Where OSA is an accepted condition, that is the most direct argument available.

What if the application is refused?

You can still be prescribed privately at full cost if it is clinically appropriate. Refusal of funding is not a clinical judgement about whether you should take it.

Talk to us

Call 0429 146 039 or email reception@vhc.org.au — Veterans Health Centre, Ipswich, Queensland. We are a veteran-focused general practice.